Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 22, 2016

View Archived Issues

Synthetic gene network maintains thyroid hormone homeostasis in experimental Graves' disease

IL-36 as a potential target for intestinal wound healing

AVROBIO to develop cell and gene therapies targeting immune-oncology and rare diseases

Cleveland HeartLab launches blood test for TMAO

Briviact approved in the U.S. for the treatment of partial-onset seizures

Boehringer Ingelheim Pharma discloses new neutrophil elastase inhibitors

Taisho Pharmaceutical patents NHE-3 inhibitors

Innov17 introduces ROR ligands

FDA accepts EOquin NDA for review

PD-1 inhibition improves memory and reduces beta-amyloid plaques in Alzheimer's disease model

The University of Tokyo and Sanofi KK sign strategic partnership agreement

Pfizer describes TrK-A inhibitors

Group in Germany patents PPARgamma antagonists

University of Oklahoma introduces RPE65 proteins

FDA extends Probuphine NDA review date

FDA accepts for review LixiLan NDA

Agilis Biotherapeutics and Waisman Biomanufacturing sign manufacturing agreement for AGIL-FA

AstraZeneca starts first-in-human trial of AZD-5634

New phase Ib study investigates TRC-105 with paclitaxel/carboplatin and bevacizumab for NSCLC

Amgen and UCB report results from phase III FRAME study of romosozumab

Chembio receives grant to develop PoC Zika diagnostics

Bayer's Kovaltry receives E.U. approval for hemophilia A

WHO approves "meran" as suffix for mRNA pharmaceuticals

Flag Therapeutics compound granted FDA orphan status for treating glioma

Serendex receives Japanese approval to start phase II/III trial of Molgradex in PAP

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...